@FierceBiotech: Novartis gears up for FDA scrutiny with a new blood cancer drug. Report | Follow @FierceBiotech
@JohnCFierce: Should Chris Viehbacher replace John Lechleiter at $LLY? Now that would be interesting. | Follow @JohnCFierce
@DamianFierce: The most metal researcher in all of science. More | Follow @DamianFierce
@EmilyMFierce: Science Cafés are growing in popularity. More | Follow @EmilyMFierce
> Teva ($TEVA) and partner Active Biotech have kicked off a Phase II trial to test the long-delayed laquinimod in patients with primary progressive multiple sclerosis. The drug is also under development for relapsing-remitting MS, progressive MS and Huntington's disease. News
> Vertex ($VRTX) has filed an FDA application for a combination of its cystic fibrosis treatments Kalydeco and lumacaftor, hoping to win an approval that would greatly expanded the number of CF patients eligible for its therapies. More
> Tekmira ($TKMR), one of the many biotechs developing treatments for Ebola, has watched its shares soar about 113% this year. Article
> Mathew Martoma, the SAC Capital Advisors trader convicted in biotech's largest insider-trading scandal, won't have to sit in prison while a federal court considers his motion for an appeal. Story
Medical Device News
@FierceMedDev: ICYMI yesterday: Spinoff Halyard Health gets boost from Ebola fears, stock up modestly in market debut. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Maryland provides seed financing to 15 med tech startups. Item | Follow @VarunSaxena2
@EmilyWFierce: This just in from the $ACT earnings call: "Actergan." | Follow @EmilyWFierce
> Former Boston Scientific engineer charged with intellectual theft. More
> Cantel Medical buys Italian healthcare manufacturer for $24.5M. News
Pharma News
@FiercePharma: ICYMI: PATH Malaria Vaccines Initiative nets $156 million from Gates Foundation. FierceVaccines story | Follow @FiercePharma
@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Here's a first: Regeneron cuts forecast after hard-charging Eylea sales miss. Article | Follow @CarlyHFierce
> Actavis rides success of branded drugs and M&A to positive Q3. More
> Allergan loses fight to block Ackman from voting for a Valeant takeover. Article
Drug Delivery News
> Distinct, compartmental reactions in an 'artificial cell' offer controlled delivery action. More
> OptiNose submits NDA to FDA. Item
> MIT spinoff SQZ Biotech nabs startup prizes for cell-squeezing delivery enhancer. Story
> AstraZeneca, University of Manchester create new center for advanced drug delivery. Article
> Study: Timing of administration an oft-overlooked factor in drug delivery. More
Diagnostics News
> Diagnostics companies homing in on rapid mobile tests to quell Ebola outbreak. Report
> Myriad signs expanded deal with AbbVie for cancer Dx. More
> AstraZeneca shells out $150M for cancer Dx outfit Definiens. Item
> LabCorp bets $6B in diversification deal with Covance. Story
> Qiagen beats the Street's Q3 numbers with success of companion Dx and next-gen TB test. Article
Pharma Marketing News
> Who's king of the orphan drug hill? BMS, Merck, Celgene and Roche, to name a few. Article
> A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing? More
> Sovaldi's not the only superhero launch: Meet the rest of the pharma Avengers. Story
> Sales speedster Eylea faces a tougher track in new DME market, Regeneron SVP says. Article